Veradermics, Incorporated (MANE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Veradermics, Incorporated (MANE) has a cash flow conversion efficiency ratio of -0.054x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.17 Million) by net assets ($391.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MANE market cap for the company's overall valuation and market capitalisation.
Veradermics, Incorporated - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Veradermics, Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Veradermics, Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veradermics, Incorporated ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Veradermics, Incorporated to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allete Inc
NYSE:ALE
|
0.031x |
|
Financière Amuse TopCo SAS
ST:ASMDEE-B
|
-0.002x |
|
Trex Company Inc
NYSE:TREX
|
-0.119x |
|
MDU Resources Group Inc
NYSE:MDU
|
0.091x |
|
Oscar Health Inc
NYSE:OSCR
|
0.685x |
|
PI Industries Limited
NSE:PIIND
|
0.022x |
|
NLC India Limited
NSE:NLCINDIA
|
0.129x |
|
Aris Mining Corporation
NYSE MKT:ARMN
|
0.070x |
Annual Cash Flow Conversion Efficiency for Veradermics, Incorporated (2023–2025)
The table below shows the annual cash flow conversion efficiency of Veradermics, Incorporated from 2023 to 2025. View Veradermics, Incorporated share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-121.01 Million | $-71.60 Million | 0.592x | +236.54% |
| 2024-12-31 | $54.66 Million | $-23.69 Million | -0.433x | +53.11% |
| 2023-12-31 | $14.62 Million | $-13.51 Million | -0.924x | -- |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more